This study investigates advanced gastrointestinal cancers. It focuses on patients whose disease has progressed after receiving standard therapy.
The study evaluates the safety and tolerability of an investigational medication when used with capecitabine. It looks at how well patients tolerate this combination and examines the relationship between a specific biomarker and treatment outcomes.
- Who can participate: Adults aged 18 and older with advanced gastrointestinal cancers can participate. Participants must have adequate blood counts and organ function, and meet specific health criteria.
- Study details: Participants will take an investigational medication with another medication.